SCHEMBL3760045

SCHEMBL3760045

O=C(O)C(=O)Nc1[c]cccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.46
PTPN11 Q06124 2/20 0.46
GPR35 Q9HC97 2/20 0.44
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP19A1 P11511 2/20 0.38
PTPRF P10586 2/20 0.38
PTPRC P08575 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPRB P23467 1/20 0.38
PTPRE P23469 1/20 0.38
PTPN6 P29350 1/20 0.38
TP53 P04637 1/20 0.35
EPHX1 P07099 1/20 0.35
TSHR P16473 1/20 0.35
EPHX2 P34913 1/20 0.35
CDK9 P50750 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6033544 0.83 SMN1; SMN2 (0.38) MEN1KMT2ATP53EPHX1TSHR
SCHEMBL9725165 0.81 SMN1; SMN2 (0.44) MEN1KMT2ATP53EPHX1TSHR
SCHEMBL5482039 0.79 NPC1 (0.32) TP53TSHR
SCHEMBL1028875 0.79 TDP1 (0.44) KMT2A
SCHEMBL11072074 0.79 SMN1; SMN2 (0.33) TP53EPHX1TSHREPHX2CDK9
SCHEMBL429187 0.78 PTPN1 (0.48) PTPN1MEN1KMT2ATP53SMN1; SMN2
SCHEMBL97108 0.78 HSD17B10 (0.48) MEN1KMT2ATSHRSMN1; SMN2
SCHEMBL55828 0.78 GAA (0.42) MEN1KMT2ATP53TSHRSMN1; SMN2
SCHEMBL11465101 0.78 SMN1; SMN2 (0.32) PTPN1PTPN11MEN1KMT2ATP53
SCHEMBL3754787 0.77 SMN1; SMN2 (0.63) MEN1KMT2ATP53EPHX1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105142634-A Oxindole carboxylic acid-based inhibitors of oncogenic protein tyrosine phosphatase-2 (SHP2) comprising Src homology-2 domain UNIV INDIANA RES & TECH CORP 2015-12-09 CN disclosed
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PTPN1 450/4885PTPN11 550/4885GPR35 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.